D.A. BORISOV¹, Z.A. DAUTOVA¹, M.S. SHOSTAK², R.R. SAMIGULLINA³

¹Ophthalmology Clinic of the North-Western State Medical University named after I.I. Mechnikov, 1/82 Zanevskiy Ave., Saint Petersburg, Russian Federation, 195196

²Clinic named after E.E. Eykhvald of the North-Western State Medical University named after I.I. Mechnikov, 41 Kirochnaya Str., Saint Petersburg, Russian Federation, 195196

³Center of Genetic and Engineering Therapy of the North-Western State Medical University named after I.I. Mechnikov, 41 Kirochnaya Str., Saint Petersburg, Russian Federation, 195196

 Contact:

Borisov D.A. ― Ophthalmologist, e-mail: borisov-spb1978@yandex.ru

Dautova Z.A. ― D. Med. Sc., Head of Ophthalmology Clinic, tel. (812) 303-51-04, e-mail: dautovazemfira@mail.ru

Shostak M.S. ― Cand. Med. Sc., Head of the Rheumatology Department, tel. (812) 303-51-11, e-mail: Mikhail.shostak@szgmu.ru

Samigullina R.R. ― Head of Center of Genetic and Engineering Therapy, tel. (812) 303-51-11, e-mail: Ruzana.samigullina@szgmu.ru

Study objective ― optimization of the algorithm for the therapy of the dry eye syndrome in rheumatoid arthritis.

Methods. The study included 29 patients (58 eyes) aged 50 to 65 years with a proven diagnosis of DES of mild and moderate severity. The patients received treatment at the Rheumatology Department of the North-West State Medical University named after I.I. Mechnikov in connection with rheumatoid arthritis (disease activity score ― DAS28 <3.2). Patients were split into groups: 16 patients (32 eyes) entered the 1^st group, these patients instilled Stillavit^® 3 times per day for 3 months. This group was split into 2 subgroups: with mild form of DES ― 8 patients (16 eyes) and moderate form ― 8 patients (16 eyes). 13 patients (26 eyes) entered the 2^nd group; these patients instilled Eyestill 3 times per day for 3 months. This group was also split into subgroups: with mild form of DES ― 7 patients (14 eyes) and moderate form ― 6 patients (12 eyes). Examination of the patients was conducted on the day of attendance and on the 90^th day of the study.

Results. According to the changes in the osmolality of the tear film and the state of the cornea with the use of vital dyes, positive dynamics was observed in the treatment of mild to moderate DES, more pronounced with the use of Stillavit^®, as compared with Eyestill.

Effectiveness of both drugs manifested in decrease in edema and hypoxia of epithelial cells and anterior surface of stroma, as well as in decrease in tear film osmolality.

Conclusions. High effectiveness of Stillavit^® in treatment of «dry eye» syndrome of mild and moderate severity in patients with RA allows recommending it as a drug of choice, and it extends the list of drugs for practical healthcare.

Key words: rheumatoid arthritis, dry eye syndrome, cornea xerosis, tears film osmolarity, tear substitutes, Stillavit^®, Eyestill.

REFERENCES

1. Nasonov E.L., Mazurov V.I., Karateev D.E. et al. Draft recommendations on the treatment of rheumatoid arthritis of the All-Russian public organization «Association of rheumatologists of Russia». Nauchno-prakticheskaya revmatologiya, 2014, no. 5, pp. 477-494 (in Russ.). DOI: 10.14412/1995-4484-2014-477-494.
2. Mazurov V.I., Trofimov E.A. Innovative methods of treatment of systemic autoimmune diseases. Vestnik Rossiyskoy akademii meditsinskikh nauk, 2015, no. 2, pp. 165-168 (in Russ.). DOI:10.15690/vramn.v70i2.1309.
3. Katargina L.A., Khvatova A.V., Denisova E.V. Effectiveness of trabeculectomy with the use of cytostatics in the treatment of uveal glaucoma in children. Oftal’mokhirurgiya, 2002, no. 3, pp. 37-40 (in Russ.), available at: http://www.fesmu.ru/elib/Article.aspx?id=83086 (accessed on: 15.01.2018)
4. Rudakova A.V. Pharmacoeconomic aspects of therapy with inhibitors of tumor necrosis factor of chronic uveitis tumor refractory to basic therapy (including those associated with juvenile idiopathic arthritis). Pediatricheskaya farmakologiya, 2011, vol. 8, no. 4, pp. 55-58 (in Russ.), available at: http://cyberleninka.ru/article/n/farmakoekonomicheskie-aspekty-terapii-ingibitorami-faktora-nekroza-opuholi-hronicheskogo-uveita-refrakternogo-k-bazisnoy-terapii-v-tom (accessed on:15.01.2018).
5. Mazurov V.I., Avlokhova S.R. Quality of life of patients with rheumatoid arthritis receiving rituximab. Klinicheskaya meditsina, 2014, vol. 92, no. 12, pp. 42-48 (in Russ.), available at: http://cyberleninka.ru/article/n/kachestvo-zhizni-bolnyh-revmatoidnym-artritom-poluchavshih-rituksimab (accessed on:15.01.2018).
6. Brzheskiy V.V., Kalinina I.V., Popov V.Yu. New possibilities of drug therapy for patients with corneal conjunctival xerosis. RMZh. Klinicheskaya oftal’mologiya, 2016, no. 1, p. 46 (in Russ.), available at: http://www.rmj.ru/articles/oftalmologiya/Novye_vozmoghnosti_medikamentoznoy_terapii_bolynyhs_rogovichno-konyyunktivalynym_kserozom/ (accessed on: 15.01.2018).
7. Egorov E.A., Romanova T.B., Kats D.V. Application of the Hiloparin-Komod ® solution in ophthalmic practice. Klinicheskaya oftal’mologiya, 2014, vol. 14, no. 4, pp. 1-6 (in Russ.), available at: http://www.rmj.ru/articles/oftalmologiya/Primenenie_rastvora_HILOPARIN__KOMOD_v_oftalymologicheskoy_praktikepilotnoe_issledovanie/#ixzz4DicNZvEp (accessed on:15.01.2018)
8. Cope A.P. Regulation of autoimmunity by proinflammatory cytokines. Curr. Opin. Immunol, 1998, vol. 10, pp. 669-676. DOI: http://dx.doi.org/10.1016/s0952-7915(98)80087-3
9. Grigor’eva N.N., Stepanova E.N., Shadrichev F.E. The use of the drug «HILABAK» in the treatment of the «Dry eye» syndrome in patients with diabetes mellitus. Oftal’mologieskie vedomosti, 2011, vol. IV, no.1, pp. 79-82 (in Russ.). DOI: http://dx.doi.org/10.17816/OV2014128-33
10. Efron N. and Morgan P. Reply. Cornea, 2007, 26 (3), pp. 382-383. DOI: 10.1097/01.ico.0000247224.48789.9b
11. 2007 report of the international dry eye workshop (DEWS). Ocul. Surf, 2007, 5 (2), pp. 65-204. DOI: 10.1016/s1542-0124(12)70080-0
12. Luchkevich V.S., Samodova I.L., Pivovarova G.M. et al. Osnovy meditsinskoy statistiki: uchebno-metodicheskoe posobie [Fundamentals of medical statistics: a teaching aid]. Saint Petersburg: izd-vo SZGMU im I.I. Mechnikova, 2014. 32 p.
13. Luchkevich V.S., Samodova I.L., Pivovarova G.M. et al. Srednie velichiny i ikh ispol’zovanie v meditsine: uchebno-metodicheskoe posobie [Average values ​​and their use in medicine: educational-methodical manual]. Saint Petersburg: izd-vo SZGMU im. I.I. Mechnikova, 2014. 35 p.
14. Fayyaz A., Kurien B.T., Scofield R.H. Autoantibodies in Sjögren’s Syndrome. Rheum Dis. Clin. North. Am, 2016, Aug, 42 (3), pp. 419-34. doi: 10.1016/j.rdc.2016.03.002. Epub, 2016, Jun 21.
15. Tincani A.1., Andreoli L., et al. Novel aspects of Sjögren’s syndrome in 2012. BMC Med, 2013, Apr 4, 11, pp. 93. doi: 10.1186/1741-7015-11-93.
16. Murbe J., Benitez Del Castillo J.M., Chen Zhuo L., et al. The Madrid triple classification of dry eye. Arch. soc. esp. oftalmol, 2003, vol. 78, pp. 587-594.
17. Egorova G.B., Mitichkina T.E, Fedorov A.A., Shamsuainova A.R. Application of an emulsion of cyclosporin to correct changes in the ocular surface when wearing contact lenses. Vestnik oftal’mologii, 2015, 1, pp. 36-42 (in Russ.). DOI: 10,1 7116/oftalma 2015131136-42.